SC declines plea to make nucleic acid tests compulsory

SC Declines Plea to Make Nucleic Acid Tests Compulsory

UPSC Prelims + Mains Study Note

1. At a Glance

• The Supreme Court of India (March 2026) refused to direct the government to make Nucleic Acid Tests (NAT) compulsory before blood transfusions, citing judicial limits on medical and fiscal policymaking. [S1]
• The case highlights the tension between judicial activism and separation of powers, particularly where courts are asked to mandate specific medical protocols with significant public-health cost implications.
• Relevant to GS-II (judiciary, health policy, constitutional limits) and GS-III (health technology, science & technology — biotech/molecular diagnostics).
• Thalassemia patients — who require lifelong, frequent transfusions — are uniquely vulnerable to transfusion-transmitted infections (TTIs) when cheaper serological tests miss infections in the window period. [S1][S2]

2. Why in the News

• March 14, 2026: A Supreme Court Bench headed by Chief Justice of India Surya Kant refused a PIL by the Sarvesham Mangalam Foundation (represented by advocate A. Velan) seeking a direction to compulsorily conduct NAT before blood transfusions. [S1]
• The SC noted it lacks "specialised knowledge about either medical science or the costs involved" and directed the petitioner to approach Health Secretaries of States for representations. [S1]
• The petition was premised on preventing "preventable tragedies" for thalassemia patients who receive repeated blood transfusions and remain vulnerable to infected blood. [S1]

3. Background & Evolution

• Blood transfusion safety in India is governed under the Drugs and Cosmetics Act, 1940 and regulated by the Central Drugs Standard Control Organisation (CDSCO), Ministry of Health & Family Welfare.
• The National Blood Transfusion Council (NBTC) and National AIDS Control Organisation (NACO) set screening protocols for blood banks.
• Mandatory serological screening in India has long relied on ELISA (Enzyme-Linked Immunosorbent Assay) for HIV, Hepatitis B (HBV), and Hepatitis C (HCV).
• NAT technology entered blood safety globally in the late 1990s–early 2000s; the US FDA began recommending it around 1999 for HIV/HCV screening.
• In India, NAT adoption has been voluntary and uneven: a Madhya Pradesh hub-and-spoke centralized NAT model (public-private partnership) screened 1,58,493 seronegative samples and found 943 (1 in 168) were NAT-reactive — infections that would have gone undetected under ELISA alone, potentially preventing 2,829 transfusion-transmitted infections. [S3]
• Despite this evidence, the national authorities have not mandated NAT across all blood banks due to cost and infrastructure constraints. [S3]

4. Core Static Facts

5. Multi-Dimensional Analysis

Legal / Constitutional

• The SC invoked the principle of institutional competence — courts lack technical expertise in medical science and cannot substitute for executive/expert bodies in setting health protocols. [S1]
• Reflects the doctrine of separation of powers: public health policy on mandating expensive diagnostics falls within executive domain (Health Secretaries, domain experts). [S1]
• Earlier SC jurisprudence (Parmanand Katara v. Union of India, Paschim Banga Khet Mazdoor Samity v. State of WB) recognized right to health under Article 21, but the court here drew limits on judicially mandating specific clinical protocols.
• The SC gave petitioner liberty to approach State Health Secretaries, preserving the federal structure for health (a State List subject — Entry 6, List II of Schedule VII).

Scientific / Technological

• NAT is a molecular diagnostics technique; it directly amplifies viral RNA/DNA using PCR (Polymerase Chain Reaction) or Transcription-Mediated Amplification (TMA). [S2]
• The key advantage is eliminating the "window period" — the time post-infection when the body has virus but antibodies are not yet detectable, making ELISA-negative blood potentially infectious. [S2]
• Madhya Pradesh data: 943 NAT-reactive, seronegative donors among 1,58,493 tested — directly illustrates clinical significance of the window period problem. [S3]
• ELISA remains the backbone of Indian blood screening; NAT is costlier, requires higher infrastructure, and is not universally available in district/rural blood banks.

Social / Equity

• Thalassemia patients (estimated 1–1.5 lakh new cases annually in India) require transfusions every 2–4 weeks throughout life, magnifying cumulative TTI exposure risk. [S1]
• Research found 15% of thalassemia patients born after 2002 were HCV-positive despite receiving serologically screened blood, underscoring ELISA's inadequacy for high-frequency transfusion groups. [S4]
• Mandating expensive NAT could impose cost burden on state health systems, potentially reducing overall blood bank coverage — disproportionately affecting poor patients.
• Access equity dimension: NAT infrastructure concentrated in urban/tertiary hospitals; rural blood banks lack capacity.

Ethical / Governance

• The SC openly questioned the motives of the petitioner NGO, raising broader questions about PIL misuse and judicial clogging with policy matters.
• A core ethical tension: precautionary principle (prevent all preventable infections) vs. resource allocation ethics (best use of limited health budgets across competing needs).
• State governments, not the Centre, bear primary constitutional responsibility for health — directing states via a writ raises federal accountability questions.

Administrative

• Blood banks are licensed under Drugs and Cosmetics Act, 1940, and screened under CDSCO's Blood Bank Regulations (Schedule F, Part XII-B).
• India has ~3,500 licensed blood banks (mix of government, hospital-based, and NGO); uneven NAT capability across them.
• A hub-and-spoke NAT model (as piloted in MP) is the pragmatic administrative solution — centralizing testing rather than equipping every blood bank. [S3]

6. Recent Developments (Last 12–18 Months)

• March 14, 2026: SC Bench (CJI Surya Kant) declines PIL seeking mandatory NAT; directs petitioner to approach State Health Secretaries. [S1]
• Previous SC hearing (prior to March 2026): Court had asked petitioner for details on cost-effectiveness of NAT vs. ELISA — signalling fiscal scrutiny before any mandate. [S1]
• Madhya Pradesh centralized NAT model: Published evidence (2024–25) from a public-private partnership demonstrated 1 in 168 seronegative donors were NAT-reactive in MP — a widely cited data point in this debate. [S3]
• WHO blood safety guidance continues to recommend NAT for high-income settings and encourages voluntary donor recruitment and quality-assured ELISA as the minimum standard for LMICs. [S2]

7. Prelims Hooks

1. NAT stands for Nucleic Acid Test (also called NAAT — Nucleic Acid Amplification Test); it detects viral RNA/DNA directly, not antibodies. [S2]
2. The window period is the interval post-infection during which ELISA is negative but the blood is infectious; NAT significantly shortens this window. [S2]
3. For HIV, NAT reduces the window period from ~22 days (ELISA) to ~10–11 days. [S2]
4. For HCV, NAT reduces the window period from ~70 days (ELISA) to ~7 days. [S2]
5. The SC declined (March 2026) to make NAT compulsory, directing the petitioner to approach State Health Secretaries instead. [S1]
6. The petition was filed by Sarvesham Mangalam Foundation (represented by advocate A. Velan), highlighting vulnerability of thalassemia patients. [S1]
7. The SC Bench that heard this case was headed by CJI Surya Kant. [S1]
8. Blood banks in India are licensed under the Drugs and Cosmetics Act, 1940, regulated by CDSCO. [S1]
9. Health is a State List subject (Entry 6, List II, 7th Schedule) — explaining why the SC directed petitioner to State Health Secretaries. [S1]
10. Madhya Pradesh's centralized NAT model found 1 in 168 seronegative donors were actually NAT-positive (virus detectable but antibodies absent). [S3]
11. Mandatory serological screening (ELISA) for HIV, HBV, HCV is currently required for all licensed blood banks in India under Drugs & Cosmetics Rules. [S3]
12. Thalassemia patients require transfusions every 2–4 weeks for life, making them uniquely vulnerable to cumulative TTI exposure. [S1]
13. The court, in a previous hearing, had asked the petitioner to compare cost-effectiveness of NAT vs. ELISA before any mandate could be considered. [S1]

8. Mains Relevance

GS Paper Mapping:

Plausible Mains Question Stems:

1. "The Supreme Court's refusal to make Nucleic Acid Testing compulsory for blood transfusions raises important questions about the limits of judicial policymaking in technical domains. Critically analyse the ruling in the context of the right to health and separation of powers." (GS-II)

2. "Transfusion-transmitted infections remain a public health challenge in India despite mandatory ELISA screening. Evaluate the feasibility and ethical implications of mandating Nucleic Acid Testing (NAT) in Indian blood banks." (GS-II / GS-III)

3. "India's blood safety architecture under the Drugs and Cosmetics Act is ill-equipped to protect vulnerable populations such as thalassemia patients. Discuss the administrative and technological reforms needed." (GS-III)

9. Related Topics to Study Next

10. Common Errors / Trap Areas

1. NAT ≠ NAAT confusion: Both terms refer to the same category of tests; NAAT (Nucleic Acid Amplification Test) is the more precise term — examiners may use either. Do not treat them as distinct.

2. Health is a State subject, not Central: A common error is to assume the Centre can directly mandate all blood bank protocols. Blood banking is under the Drugs & Cosmetics Act (Central), but health delivery/financing is predominantly State List — hence the SC directing petitioner to State Health Secretaries, not the Union Health Ministry alone.

3. ELISA detects antibodies, NAT detects viral nucleic acids: Candidates often confuse the two as interchangeable "blood tests." ELISA is an antibody/antigen assay; NAT directly detects RNA/DNA — fundamentally different principles and window periods.

4. Thalassemia vs. Haemophilia confusion: Both require transfusions, but thalassemia (genetic red-cell disorder) requires regular packed RBC transfusions; haemophilia requires clotting factor concentrates, not typically whole blood. The NAT debate centres on thalassemia.

5. SC "refused" ≠ SC ruled NAT is unsafe: The SC did not rule against NAT on medical grounds. It declined to judicially mandate it, citing institutional competence limits — a procedural/constitutional ruling, not a clinical one.

11. Sources

• [S1] "SC declines plea to make nucleic acid tests compulsory" — The Hindu, March 14, 2026 — (Tier 4) (Primary article, fallback source — article content provided)
• [S2] WHO EMRO: "Blood transfusion and hepatitis: what does it take to prevent new infections?" — https://www.emro.who.int/emhj-volume-24-2018/volume-24-issue-6/blood-transfusion-and-hepatitis-what-does-it-take-to-prevent-new-infections.html — (Tier 2)
• [S3] "Blood Safety: The Madhya Pradesh Centralized Nucleic Acid Testing (NAT) Model for Blood Donor Screening" — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12869267/ — (Tier 3, peer-reviewed medical research)
• [S4] "Screening Donated Blood for Transfusion Transmitted Infections by Serology along with NAT and Response Rate to Notification of Reactive Results: An Indian Experience" — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248483/ — (Tier 3, peer-reviewed)